Analyst consensus rating
Intellia Therapeutics Analyst Rating: none
Direct answer
Intellia Therapeutics's consensus rating is none.
18 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $23.11.
Forecast evidence checked November 1, 2026.
Get free Intellia Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $12.47
- Average price target
- $23.11
- High price target
- $61.00
- Low price target
- $8.00
- Low target gap
- -35.8%
- Target upside
- +85.3%
- High target gap
- +389.2%
- Target range width
- 425%
- Consensus rating
- none
- Analysts
- 18
- Evidence date
- November 1, 2026
- Valid through
- November 8, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Intellia Therapeutics?
Intellia Therapeutics has a verified none consensus. The same dataset has an average price target of $23.11.
How far are Intellia Therapeutics's low and high targets from the recorded price?
The low target implies -35.8%, while the high target implies +389.2%.
How many analysts are included in Intellia Therapeutics's consensus?
The verified consensus includes 18 analysts.
How is Intellia Therapeutics's target upside or downside calculated?
The average target of $23.11 is divided by the recorded price of $12.47, then one is subtracted to produce +85.3%. This does not guarantee a future return.
When was Intellia Therapeutics's analyst forecast verified?
The data was verified on 2026-11-01. The dataset is valid through 2026-11-08.